Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept vs PRP for Proliferative Diabetic Retinopathy
NCT02911311Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of conbercept in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Mean visual acuity change (BCVA) at 12 months. Status: unknown.
02
Drugs
conbercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02911311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911311.